Krishnansu S. Tewari, MD, discusses the excitement around immunotherapy in cervical cancer.
Krishnansu S. Tewari, MD, associate professor, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of California, Irvine, discusses the excitement around immunotherapy in cervical cancer.
Scientifically, it makes sense to look at these therapies in this setting, Tewari says. The mutational burden of cervical cancer is similar to other solid tumors where immunotherapy has had positive results, according to phase III findings.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More